Abstract: This organ protecting member (1) is used when an opening portion (36a) is formed in an abdominal wall (30) and an intestinal tract (32) is exposed to a body surface (33) from the opening portion (36a) to temporarily construct an artificial anus (34). The organ protecting member (1) includes a movement restricting part (support string (12)) configured to restrict movement of a portion of the lifted intestinal tract (32) on which the artificial anus (34) is constructed toward an abdominal cavity (35); and a cover (11) disposed between the intestinal tract (32) and an inner wall surface (36b) of the opening portion (36a) of the abdominal wall (30).

Abstract: The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.

Abstract: An embodiment according to the present invention provides a kit or device for detection of bladder cancer, and a method for detecting bladder cancer. An embodiment according to the present invention relates to: a kit or device for detection of bladder cancer, including a nucleic acid(s) capable of specifically binding to an miRNA(s) or a complementary strand(s) thereof in a sample from a subject; and a method for detecting bladder cancer, including measuring the miRNA(s) in vitro.

Abstract: A pharmaceutical composition tor preventing treating cancer including a 3-ketoacyl CoA thiolase (ACAA) inhibitor and a carat in acylcarnitine carrier (CAC) inhibitor represented by Formula below: where R1 to R4 are each independently H, C1-6 alkyl substituted or unsubstituted with one or more halogen, or alkoxy substituted or unsubstituted with one or more halogen, and where the halogen is selected from F, Cl, Br, and I.

Abstract: It is intended to provide a kit or a device for the detection of lung cancer and a method for detecting lung cancer. The present invention provides a kit or a device for the detection of lung cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA in vitro.

Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.

Abstract: The present invention relates to a stemness-suppressing composition comprising an OCT4 function-inhibiting peptide and, more particularly, to a composition comprising a peptide as an effective ingredient for suppressing the stemness of various stem cells such as general stem cells, cancer stem cells, and the like, wherein the peptide inhibits the function of OCT4 by inducing the phosphorylation of OCT4. OCT4 function-inhibiting peptides of the present invention are expected to find applications in various fields through the suppressive activity thereof against stemness of stem cells.

Abstract: This invention provides a kit or device for detection of prostate cancer and a method for detecting prostate cancer. This invention provides a kit or device for detection of prostate cancer comprising a nucleic acid capable of specifically binding to an miRNA in a sample from a subject or a complementary strand thereof and a method for detecting prostate cancer comprising measuring the miRNA in vitro.

Abstract: The present invention relates to a method for providing information for cancer diagnosis or prognosis prediction by measuring the expression level of TIM-3 in CD11b+ cells. In addition, the present invention relates to a composition for cancer diagnosis or prognosis prediction comprising an agent for measuring the expression level of TIM-3 in CD11b+ cells or uses thereof. Since glial TIM-3 responds positively and uniquely to brain tumors and has specific intracellular and intercellular immune modulatory roles that may differ from TIM-3 in brain tumor microenvironment T cells, it can be effectively used in a composition or a method for providing information for cancer diagnosis or prognosis prediction.

Abstract: A processor encodes a target image to derive at least one first feature amount indicating an image feature for an abnormality of a region of interest included in the target image. In addition, the processor encodes the target image to derive at least one second feature amount indicating an image feature for an image in a case in which the region of interest included in the target image is a normal region.

Abstract: This application provides a kit or a device for detection of lung cancer, comprising a nucleic acid(s) for detecting a miRNA(s) in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA(s) in vitro.

Abstract: A medical system includes an endoscope that captures an image including an object, a moving device that includes a robot arm and that moves the endoscope in a body, and a controller that controls the moving device on the basis of the position of the object. The controller is configured to control the moving device in a first control mode in which the endoscope is caused to follow the object at a first speed and a second control mode in which the endoscope is caused to follow the object at a second speed lower than the first speed. The controller controls the moving device in the first control mode when the object is located outside a predetermined three-dimensional region set in a field of view of the endoscope. The controller controls the moving device in the second control mode when the object is located in the predetermined three-dimensional region.

Abstract: An endoscope system includes an endoscope, a moving device that moves the endoscope, a storage unit, and a processor. The storage unit stores first position information and first rotation angle information, which defines a rotation angle of an endoscope image of a first region, on the first region in a subject and second position information and second rotation angle information, which defines a rotation angle of an endoscope image of a second region, on the second region in the subject. The processor calculates third rotation angle information on a third region in the subject based on the first and second position information, the first and second rotation angle information, and third position information on the third region. If the third region includes the current imaging region, the processor rotates the endoscope image based on the third rotation angle information and outputs the rotated endoscope image to the display device.

Abstract: A controller controls an image that is captured by an image sensor of an endoscope and is displayed on the display screen of a display device. The controller includes a processor. The processor acquires a first image that is an image captured by the image sensor, detects a first angle of a surgical instrument, and generates a second image rotated with respect to the first image on the basis of the first angle and a predetermined target angle. The first angle is an angle formed by the surgical instrument in the first image with respect to a predetermined reference line that is set with respect to a plane of the first image. A second angle formed by the surgical instrument in the second image with respect to the predetermined reference line is equal to the predetermined target angle.

Abstract: A method includes: acquiring data including moving image obtained by photographing a target and annotation images each indicative of a region of the target in each of frame images in the moving image; executing a process using the data. The process includes: detecting the target in the frame images; inputting, to an auto-encoder, an image obtained by combining partial images including the target and peripheral region images of the target detected in a given number of preceding and succeeding second frame images in a time series of the moving image of a first frame image; inputting a partial image corresponding to the first frame image to a neural network performing a segmentation; updating parameter of the auto-encoder and the neural network based on a difference between an image obtained by combining images from the auto-encoder and the neural network and a partial image of the annotation image.

Abstract: A controller controls a movement of an endoscope to cause the endoscope to follow a surgical instrument. The controller includes a processor. The processor acquires position information including the position of the surgical instrument, acquires scene information associated with a procedure scene to be observed through the endoscope, determines an offset parameter, which determines the position of the target point with respect to a predetermined fiducial point in the field of view of the endoscope, of a target point on the basis of the scene information, sets the position of the target point with respect to the fiducial point on the basis of the offset parameter, and causes the endoscope to follow the surgical instrument such that the surgical instrument is disposed at the target point, by controlling a movement of the endoscope on the basis of the position of the target point and the position of the surgical instrument.

Abstract: It is intended to provide a rapid, convenient, and highly accurate method for determining the prognosis of cancer. The present invention provides a method for determining a tissue having renal cell carcinoma, comprising: (1) subjecting sample DNA to ion exchange chromatography, wherein the sample DNA is obtained by treating target genomic DNA prepared from a renal tissue of a subject with bisulfite, followed by PCR amplification; (2) calculating a derivative value of a detection signal of the chromatography; and (3) determining the renal tissue as being a tissue having renal cell carcinoma having poor prognosis when the derivative value calculated in the step (2) has two or more maximums.

Abstract: A medical information processing apparatus according to an embodiment includes a processing circuitry. The processing circuitry acquires operation information of a medical worker for medical treatment information of a target patient or operation information of a medical worker for medical treatment information of a similar patient who is similar to the target patient. Based on the operation information, the processing circuitry calculates the concordance rate between a period for which the medical treatment information of the target patient or the medical treatment information of the similar patient is referred to and the period for which the medical treatment information of the target patient is displayed. The processing circuitry performs display of information about the concordance rate.

Abstract: An object of the present invention is to provide a kit or a device for the detection of prostate cancer and a method for detecting prostate cancer. The present invention provides a kit or a device for the detection of prostate cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting prostate cancer, comprising measuring the miRNA in vitro.

Abstract: An object of the present invention is to provide an anticancer drug capable of treating cancer by finding a target molecule specifically expressed in cancer cells and by specifically acting on the target molecule, and to provide a cancer testing method including a step of measuring the target molecule in a sample. The present invention provides an anticancer drug containing, as an active ingredient thereof, an anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof. In addition, the present invention provides a cancer testing method including a step of measuring the amount of TMEM-180 in a sample collected from a subject.